Gestational Diabetes Market Report 2025

This Gestational Diabetes market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The gestational diabetes market size has grown strongly in recent years. It will grow from $8.37 billion in 2024 to $9.14 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historical period can be attributed to various factors, such as the increasing prevalence of diabetes, advancements in blood glucose measurement accuracy, a rise in the number of insurance providers, and a growing population of individuals with diabetes. Furthermore, the expanding diabetic population has played a significant role in driving this growth.

The gestational diabetes market size is expected to see strong growth in the next few years. It will grow to $12.9 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth projected for the forecast period is driven by various factors, including the increasing prevalence of obesity, greater adoption of cloud-based project solutions, and the rising use of related devices and applications. Additionally, the surge in diabetes cases due to unhealthy lifestyle choices, heightened public health awareness, and escalating diabetes rates are significant contributors. Key trends anticipated during this period include the emergence of digital diabetes management apps, closed-loop control systems, advancements in diabetes management technologies, enzymatic innovations, and other cutting-edge medical advancements.

The growing prevalence of obesity is expected to drive the expansion of the gestational diabetes market in the future. Obesity refers to individuals with a body mass index (BMI) of 30 or higher, indicating excessive body fat that can lead to significant health risks. The rise in obesity is influenced by factors such as sedentary lifestyles, the increased intake of high-calorie processed foods, genetic predispositions, and limited access to healthy food and exercise options. Gestational diabetes treatment is particularly important for the obese population, as their increased risk of insulin resistance and excessive weight gain during pregnancy can cause complications for both the mother and baby if left untreated. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental agency, reported that approximately 1 in 8 people worldwide were living with obesity in 2022. This includes 2.5 billion adults aged 18 and older classified as overweight, of which 890 million were living with obesity. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under 5 years old were overweight, and more than 390 million children and adolescents aged 5 to 19 years were overweight, including 160 million living with obesity. As a result, the increasing obese population is driving the growth of the gestational diabetes market.

Leading companies in the gestational diabetes market are focusing on the development of advanced products, such as diagnostic kits, to offer quick, accurate, and convenient methods for early detection of the condition. A diagnostic kit for gestational diabetes is a medical tool used to measure blood glucose levels and detect abnormal glucose tolerance in pregnant women, helping in the early identification and management of the condition. For example, in August 2024, DirectSens GmbH, a biotechnology company based in Austria, introduced the XpressGT RUO kit. This diagnostic kit is designed to detect gestational diabetes, endometriosis, insulin resistance, and liver disease. It measures 2-hydroxybutyrate (2-HB) levels in venous blood, a substance naturally produced by the liver during its normal functions. Elevated 2-HB levels are linked to increased reductive stress, which is associated with various endocrine and obesity-related disorders, including insulin resistance. The kit is compatible with any clinical analyzer and provides results in just 8 minutes, offering a fast and efficient diagnostic solution.

In April 2024, Digostics, a diabetes home-testing provider based in the UK, partnered with AgaMatrix Europe to advance gestational diabetes screening. This collaboration grants AgaMatrix exclusive rights to distribute Digostics' home oral glucose tolerance testing (OGTT) service, GTT@home, to the UK National Health Service (NHS). By utilizing its strong connections and customer base within NHS maternity services, along with its extensive expertise in gestational diabetes monitoring, AgaMatrix aims to accelerate the introduction of GTT@home in the UK market. AgaMatrix Europe is a UK-based company specializing in the production of blood glucose monitoring solutions.

Major players in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc.

North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gestational diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gestational diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gestational diabetes is a type of diabetes that arises during pregnancy when the body fails to produce enough insulin to adequately regulate blood sugar levels. This condition usually emerges in the second or third trimester and can occur in women without a prior history of diabetes. Gestational diabetes poses risks to both the mother and the baby, including high birth weight, premature delivery, and an increased likelihood of developing type 2 diabetes later in life for both. Management typically involves adjustments to diet, regular exercise, blood sugar monitoring, and, if necessary, insulin therapy to support a healthy pregnancy and childbirth.

Gestational diabetes is categorized into several types, including Type A1, Type A2, and other forms. Type A1 refers to gestational diabetes mellitus (GDM) that develops during pregnancy due to insufficient insulin production to meet the increased demands of this period. Treatment strategies often include blood sugar monitoring, medication, and lifestyle interventions, which may be delivered orally, intravenously, or through other methods. These interventions are commonly implemented in hospitals, clinics, home care settings, and diagnostic centers.

The gestational diabetes market research report is one of a series of new reports that provides gestational diabetes market statistics, including gestational diabetes industry global market size, regional shares, competitors with gestational diabetes market share, detailed gestational diabetes market segments, market trends, and opportunities, and any further data you may need to thrive in the gestational diabetes industry. This gestational diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gestational diabetes market consists of revenues earned by entities by providing services such as nutritional counseling, medication management, telemedicine services, lifestyle and exercise guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational diabetes market also includes sales of metformin, glyburide, and insulin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.